Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NLK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NLK Recombinant Protein (Active/Mutant) High purity (>90%), Endotoxin Controlled. Sequence Verified. Sf9 Insect Cell / E. coli Expressed. |
View NLK Products |
| Gene Delivery | NLK Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View NLK Products |
| Benchmark Ab | Anti-NLK Antibody Recombinant sequence-verified positive control for Western Blot and IP. |
View NLK Products |
| Validator | NLK siRNA Set For gene knockdown and specificity verification. |
View NLK Products |
| Related Target A | ATXN1 Direct downstream substrate of NLK; critical node in Spinocerebellar Ataxia Type 1 (SCA1) pathogenesis. |
View ATXN1 Products |
| Related Target B | STAT3 NLK phosphorylates and regulates STAT3 transcriptional activity, modulating tumor progression and neuroinflammation. |
View STAT3 Products |
| Related Target C | CTNNB1 Beta-catenin; NLK regulates the Wnt/beta-catenin pathway via phosphorylation of TCF/LEF factors. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-purity active kinase for enzymatic screening | Sf9 insect cell-expressed active NLK, maintaining native phosphorylation states and kinase activity |
| Selectivity screening against homologous MAPKs/CDKs | Comprehensive MAPK and CDK family recombinant protein panels strictly verified by mass spectrometry |
| Lack of reliable control antibodies for cellular validation | Recombinant monoclonal benchmark antibodies with sequence-verified specificity |
| False positives in phenotype-based small molecule assays | Sequence-verified siRNA pools included for target-specific knockdown controls |
Live NLK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Nemo-Like Kinase (NLK), an atypical proline-directed serine/threonine kinase, is an emerging frontier spanning oncology and neurodegenerative disease. As a critical integrator of the Wnt/beta-catenin, Notch, and non-canonical MAPK pathways, NLK acts as a molecular rheostat. The race for NLK therapeutics is intensifying, with major players shifting focus from traditional non-specific kinase inhibitors to highly selective small molecules, proteolysis targeting chimeras (PROTACs), and RNA-targeted therapeutics (ASOs/siRNAs). As first-generation candidates progress through preclinical validation, the next wave of R&D is targeting tissue-specific delivery and isoform-selective modulation to bypass systemic homeostatic toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Emerging Biotechs | Colorectal Cancer, Glioma, Prostate Cancer | Kinase Activity & Selectivity assays (Need active recombinant NLK & homolog panels) |
| ASO / siRNA | Ionis Pharmaceuticals, Alnylam | Spinocerebellar Ataxia Type 1 (SCA1), ALS | Cellular knockdown and target validation (Need validated siRNA & Lentivirus) |
| PROTACs | Targeted Protein Degradation Biotechs | Advanced Solid Tumors | Target engagement & degradation kinetics (Need recombinant NLK & stable cell lines) |